por
Thomas Dworetzky, Contributing Reporter | October 23, 2018
On Tuesday, the company released Q3 earnings. The report,
according to MarketWatch, showed that “Watson health had seen growth,” though its parent “cognitive solutions” division saw revenues fall 6 percent from the previous year.
Business concerns had also arisen when reports surfaced in June of layoffs at Watson Health. At that time, IBM acknowledged that layoffs hit its Watson Health segment, but that, “this activity affects a small percentage of our global Watson Health workforce,” noting that, “IBM is continuing to reposition our team to align with our focus on the high-value segments of the IT market. We continue to hire aggressively in critical new areas that deliver value for our clients and IBM.”
Ad Statistics
Times Displayed: 2832
Times Visited: 27 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
Some reports, including one from May 25 on tech news site The Register, said pink slips were said to hit 50 to 70 percent of IBMers in the Watson Health division.
The layoffs appear to have zeroed-in on workers at a number of recent firms, picked up to pump Watson's health cred, including health data player Truven, picked up in 2016 for $2.6 billion; medical imaging player Merge, for which IBM dropped $1 billion in 2015; and 2015 buy Phytel, a healthcare management player.
The layoffs reportedly happened primarily in Dallas, Ann Arbor, Cleveland and Denver, and abroad.
Back to HCB News
